Investment decisions into the hydrogen business have doubled in the past year, according to the IEA.
October 3, 2024, 11:33 AM GMT+9
It's important to keep an eye on whether it will become an economic trend in the future.
According to a report released by the International Energy Agency (IEA) on the 2nd, investment decisions in hydrogen-related businesses have doubled in the last 12 months. However, amidst industry uncertainties, processing capacity and demand remain low.
As a result of investment decisions, hydrogen production will increase to five times the current level by 2030. In the past 12 months, investment decisions have accounted for over 40% by China. On the other hand, demand targets only slightly exceed 25% of production plans. The IEA has expressed the view that the progress in the hydrogen sector so far is not sufficient to achieve climate change goals.
Furthermore, most businesses are in the early stages, with risks in business plans such as uncertainty in demand, difficulty in funding, and unclear regulations by authorities.
The IEA's Executive Director, Mr. Birol emphasized that policymakers and developers should support demand creation and aim for cost reduction and regulatory clarification. This will lead to further expansion of investment in this sector.
Global hydrogen demand is currently focused on refining and chemical sectors, and will further expand with the...

[Market Eye] Stocks: The morning Nikkei average rebounded, supported by a weaker yen. The candlestick chart shows a hesitant 'whale curtain' pattern.
October 3, 2024, 11:51 AM GMT+9 (excerpt)
<11:40> The morning Nikkei average rebounded, supported by a weaker yen. The candlestick chart shows a hesitant 'whale curtain' pattern.
In the morning session of the Tokyo stock market, the Nikkei average rebounded to 38,655.03, up 846.27 yen compared to the previous business day. Supported by a 3-yen rise in the dollar/yen rate from the previous day, export-related stocks were firm. Domestic semiconductor-related and high-tech stocks were also strong due to the rise in U.S. semiconductor stocks. However, the chart pattern shows a hesitant market sentiment with a 'whale curtain' appearance.
After opening at 650 yen, the Nikkei average temporarily rose to 38,567.75 yen, up 1047 yen. In the market, there is a voice saying, 'As Prime Minister Shigeru Ishiba is making adjustments to a more practical approach, the depreciation of the yen has led to a sense of security.' (Jun Kitazawa, Deputy Head of Investment Information Group, Miki Securities).
The dollar temporarily rose to the 147 yen level, supporting export-related stocks such as automobiles. Domestic semiconductor and high-tech stocks were generally solid. Jensen Huang, CEO of American Nvidia...

Concerns arise over prolonged confusion due to deadlock in negotiations on the second day of the US port strike.
October 3, 2024, 8:02 AM GMT+9 (excerpt).
In ports on the US East Coast and Gulf Coast, a strike by 45,000 workers entered its second day. According to sources, negotiations between labor and management are currently not scheduled. Companies relying on maritime transport are increasingly concerned about the prolonged confusion.
As a result of the strike by the International Longshoremen's Association (ILA), which represents port workers, transportation of various goods such as food and automobiles has been disrupted at dozens of ports from Maine to Texas. Analysts warn that it could result in economic losses of billions of dollars per day.
The US administration is pressuring management to raise the amount of the new labor contract offer and secure the union's agreement towards ending the strike.

eli lilly and co's obesity drug shortage issues resolved = FDA
October 3, 2024 10:55 AM GMT+9 (excerpt)
The shortage of Eli Lilly and Co.'s main obesity treatment drug due to increased demand has been resolved, as revealed on the U.S. Food and Drug Administration (FDA) website on the 2nd.
Eli Lilly and Co.'s obesity treatment drug shortage resolved, impacting FDA-approved combination drug suppliers.
October 3, 2024 11:03 JST
Shortage of 'Zeptbound' and 'Manjaro' has been resolved, according to FDA announcement.
Due to being listed in the shortage list, pharmacies were able to sell compounded drugs.
Supply shortage of eli lilly and co's obesity and diabetes treatment drugs has been resolved. The US authorities revealed on the 2nd. During the shortage, compounded drugs using the same ingredients had gained popularity, but the situation may change drastically.
The US Food and Drug Administration (FDA) announced that the shortage of Lilly's 'Zeptbound' and 'Manjaro' has been resolved. It pointed out that there are legal restrictions on manufacturing generic drugs approved by the FDA only when there is no shortage.
FDA announced that Eli Lilly and Co's obesity and diabetes treatment drugs are in short supply...

$Direxion Daily Semiconductor Bull 3x Shares ETF (SOXL.US)$
Hello.
It's an extra early financial estimates for tonight, meow~I posted early because it's easy to understand, meow~
N touched the bulls-eye of the 121 micro Veru Inc target resistance
If it can break through the swing high of 122.44, there is a high possibility of continuing to rise.
However, if it does not break through the swing high, the potential for a breakdown remains high, and the target is 112.The resistance levels that must be surpassed to continue rising are 123.07/125.54 nya~n
Whether L exceeds or falls below 35.50 is the key nya~n

$NVIDIA (NVDA.US)$
Jensen Huang, CEO of Nvidia (nasdaq: NVDA), stated that demand for the latest GPU, Blackwell, is progressing well.
"Blackwell is in full production," Huang said in an interview with CNBC on Wednesday. "Blackwell is on schedule, and the demand for Blackwell is unprecedented. Everyone wants the most, and everyone wants to be the first."
Blackwell GPU has already been released for artificial intelligence applications, datacenters, and industrial customers. They will be available to consumers in 2025.

Eli Lilly and Co. to invest $4.5 billion in new development site construction in Indiana, USA.
October 3, 2024, 8:06 AM GMT+9
US pharmaceutical giant Eli Lilly announced on the 2nd that it will invest $4.5 billion to build a new research and development site in Indiana. This will bring the total investment for the US announced since 2020 to over $23 billion.
The new site, Lilly Medicine Foundry, will focus on developing new methods related to pharmaceutical manufacturing and expanding the production of investigational drugs. It plans to hire 400 full-time engineers, scientists, research technicians, and others, and is scheduled to start operations in late 2027.
Deere & Co CEO David Rickes said in an interview with CNBC that this site has the potential to increase the company's production capacity by 400%.
According to the company, the new technology developed at the Medicine Foundry will be utilized for comprehensive production at other manufacturing sites.